MIRM Q3 2025 Earnings — Mirum Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

MIRMMirum Pharmaceuticals, Inc.

$5B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$133M+47.2% YoY

Gross Profit

$107M80.8% margin

Operating Income

$3M2.0% margin

Net Income

$3M2.2% margin

EPS (Diluted)

$0.05

QoQ Revenue Growth

+4.1%

Cash Flow

Operating Cash Flow

$40M

Free Cash Flow

$39M

Stock-Based Comp.

$18M

Balance Sheet

Total Assets

$785M

Total Liabilities

$493M

Stockholders' Equity

$292M

Cash & Equivalents

$282M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$133M	$90M	+47.2%
Gross Profit	$107M	$70M	+54.5%
Operating Income	$3M	-$13M	+120.5%
Net Income	$3M	-$14M	+120.4%

Revenue Segments

Product

$133M100%

Geographic Segments

UNITED STATES

$104M78%

Rest Of World

$29M22%